G-protein-coupled receptors are the largest class of cell-surface receptors, and these membrane proteins exist in equilibrium between inactive and active states [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Conformational changes induced by extracellular ligands binding to G-protein-coupled receptors result in a cellular response through the activation of G proteins. The A 2A adenosine receptor (A 2A AR) is responsible for regulating blood flow to the cardiac muscle and is important in the regulation of glutamate and dopamine release in the brain 14 . Here we report the raising of a mouse monoclonal antibody against human A 2A AR that prevents agonist but not antagonist binding to the extracellular ligand-binding pocket, and describe the structure of A 2A AR in complex with the antibody Fab fragment (Fab2838). This structure reveals that Fab2838 recognizes the intracellular surface of A 2A AR and that its complementaritydetermining region, CDR-H3, penetrates into the receptor. CDR-H3 is located in a similar position to the G-protein carboxy-terminal fragment in the active opsin structure 1 and to CDR-3 of the nanobody in the active b 2 -adrenergic receptor structure 2 , but locks A 2A AR in an inactive conformation. These results suggest a new strategy to modulate the activity of G-proteincoupled receptors.
The structures of G-protein-coupled receptors (GPCRs) in an inactive conformation solved recently [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] greatly advance our understanding of the molecular signalling mechanisms of the receptors. The first details of GPCR activation were provided by the structure of bovine opsin in an active conformation complexed with a G-protein C-terminal peptide 1 (GaCT). Most recently, determination has been made of the crystal structures of b 2 adenosine receptor (b 2 AR) in an active state with a camelid antibody fragment 2 (nanobody Nb80) and with a heterotrimeric G s protein 13 . In these structures, the complementarity-determining region (CDR-3) of Nb80 and the C-terminal a-helix of a subunit (Ga s ) of G s protein were located in the same pocket as was GaCT in the opsin structure. Nb80 and G s protein change the conformational equilibrium of b 2 AR toward the active state in a similar manner, thereby substantially increase their agonist affinities 2, 13 .
A 2A AR is responsible for regulating blood flow to the cardiac muscle and is important in the regulation of glutamate and dopamine release in the brain 14 . Caffeine is a well-known antagonist of this receptor. Strong epidemiological evidence indicates that coffee drinkers have a lower risk of Parkinson's disease 15 . The structure of A 2A AR has been reported 9,16 as a complex with both an antagonist (ZM241385) and an agonist (UK-432097). These structures reveal the molecular framework of the receptor; however, in both cases the intracellular loop 3 (ICL3), critical for G-protein binding, has been replaced by T4 lysozyme (T4L).
Here we report the crystal structure of A 2A AR with complete ICL3 in complex with a mouse monoclonal-antibody Fab fragment, Fab2838. A 2A AR was expressed in Pichia pastoris and the antibody was raised against the purified receptor with antagonist (ZM241385) bound using the conventional mouse hybridoma system combined with improved immunization and screening methods (Methods). Fab2838, a Fab fragment generated from one (IgG2838) of the obtained antibodies, completely inhibited binding of the agonist [ 3 H]-59-N-ethylcarboxamido adenosine ([ 3 H]-NECA) but did not affect binding of the antagonist [ 3 H]-ZM241385 ( Fig. 1a, d and Supplementary Fig. 2 ). The results were confirmed by competition binding assays (Supplementary Discussion and Fig. 1 ). These findings suggest that Fab2838 induces an inactive conformation (that is, one to which agonist cannot bind) of the A 2A AR ligand-binding pocket without blocking the ligand-binding site.
We crystallized A 2A AR with Fab2838 in the presence of ZM241385 and solved the structure at a resolution of 2.7 Å (Supplementary Table 2 ). Because the occupancy of ZM241385 in the structure was low for unknown reasons, we repeated the experiments and obtained a higher occupancy structure at 3.1 Å (Supplementary Table 2 and Supplementary Figs 3 and 4). Except for the occupancy of the ligand, the two structures are almost identical (root mean squared deviation of Ca, 0.57 Å ) (Supplementary Table 2 ). ZM241385 occupies the ligandbinding pocket on the extracellular side by making hydrophobic interactions with Phe 168 5.29 and Ile 274 7.39 and hydrogen bonds with Asn 253 6.55 as observed in the A 2A AR-T4L structure ( Supplementary Fig. 4 ) (superscripts indicate residue numbers as per the Ballesteros-Weinstein scheme 17 ). Although the overall structure of A 2A AR in the A 2A AR-Fab2838 complex is similar to that of A 2A AR-T4L (Protein Data Bank code, 3EML; root mean squared deviation of Ca, 0.85 Å ), there is a major difference around the intracellular portions of helices V and VI; these are connected by ICL3, which in A 2A AR-T4L is replaced with T4L ( Supplementary Fig. 5 ). In our structure, ICL3 forms two regular helices-effectively continuations of helices V and VI, respectively-connected by a short turn ( Supplementary Fig. 6a ).
The A 2A AR-Fab2838 structure has a modified 'ionic lock' where Glu 228 6.30 (helix VI) and Arg 102 3.50 of the D/ERY motif (helix III) interact through a water molecule (W1; Fig. 2c, d ). In the inactive bovine rhodopsin structure, the equivalent residues form a direct salt bridge 3 ( Supplementary Fig. 7 ). Arg 102 3.50 of A 2A AR-Fab2838 forms salt bridges or hydrogen bonds with Asp 101 3.49 and Tyr 112 in ICL2 and with Thr 41 2.39 as observed in the A 2A AR-T4L structure (Supplementary Fig. 5b ). Because of the insertion of the water molecule, Glu 228 6.30 shifts towards the cytoplasmic space, as compared with the equivalent residue in rhodopsin (Glu 247 6.30 ), resulting in the formation of a salt bridge with Arg 220 in the short helical turn of ICL3. This interaction may be important in the formation of the helical structure in ICL3. The ionic lock has not been observed in the crystal structures of other inactive GPCRs 6-11 , including A 2A AR-T4L, except for the D3 dopamine receptor 12 . This may be because the ICL3 loops in the other structures were modified to stabilize the protein. While this paper was under review, the crystal structures of thermostabilized A 2A AR mutants with native ICL3 were published 18, 19 . The antagonist-bound inactive structures have the ionic lock 19 . Thus, the ionic lock of A 2A AR seems to stabilize the inactive conformation of the protein, which is why the receptor has a low basal activity.
Fab2838 binds on the intracellular side of the receptor ( Fig. 2a ). CDR-H3 of Fab2838 is unusually long and penetrates a pocket formed by helices II, III, VI and VII ( Fig. 2b ). CDR-H3 interacts with the surrounding helices by forming six hydrogen bonds and eight van der Waals contacts ( Fig. 2c, d ). The most extensive interactions are with helix II (mainly through hydrogen bonds) and helix VI (mainly through van der Waals contacts). In addition, a hydrogen bond network including two water molecules is observed between CDR-H3 and helices III and VI ( Fig. 2c, d ). This hydrogen bond network together with the van der Waals interactions seem to stabilize the modified ionic lock interaction between Glu 228 6.30 (helix VI) and Arg 102 3.50 (helix III) discussed above. Other complementarity-determining regions further stabilize the A 2A AR-Fab2838 complex by forming 14 hydrogen bonds with helices VI and VIII and ICL1, ICL2 and ICL3 ( Fig. 2b) . 
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The extensive interactions explain the high affinity of Fab2838 (dissociation constant, K d 5 4.4 nM) ( Supplementary Fig. 8 ).
The binding site of Fab2838 CDR-H3 in A 2A AR is similar to those of Nb80 CDR-3 in b 2 AR 2 and GaCT in opsin 1 . A critical difference is that Fab2838 stabilizes an inactive conformation whereas the others recognize active conformations of the receptors. These structures are compared in Fig. 3 . In the opsin structure, GaCT, which forms a short a-helix, fits into a large pocket formed by helices II, III, V, VI and VII interacting with the Arg residue of the D/ERY motif in helix III (Fig. 3 , left panels). CDR-3 of Nb80 in the b 2 AR structure binds in a similar position to GaCT although CDR-3 forms a b-hairpin 1 (Fig. 3, middle  panels) . CDR-H3 of Fab2838 also forms a b-hairpin but induces a differently shaped binding pocket (Fig. 3c ). In the b 2 AR structure, CDR-3 of Nb80 is positioned between helices III and VI, whereas in the A 2A AR structure CDR-H3 of Fab2838 is ,6 Å closer to helices II and VII ( Fig. 3b and Supplementary Fig. 9 ). This allows the close association of helices III and VI and the formation of the modified ionic lock between Arg 102 3.50 in helix III and Glu 228 6.30 in helix VI, consequently stabilizing the inactive conformation. In the b 2 AR/G sprotein complex structure, the C-terminal a-helix (a5) of Ga s also binds in a similar position to CDR-H3 13 (Supplementary Fig. 10 ). The conformational changes of a5 together with the Ga s aminoterminal region induced by the activated receptor has been proposed to result in a nucleotide exchange from GDP to GTP in Ga s and to subsequent dissociation of the subunit from the receptor 20 . Thus, the binding pocket formed by helices II, III, VI and VII seems to be the key site for the signal transfer between GPCRs and G proteins.
A possible inactivation mechanism of A 2A AR by Fab2838 is summarized as follows. Agonist binding induces large displacements of the intracellular ends of helices III, VI and VII 16, 18 , which are essential to form the G-protein binding pocket 13, 20 (Supplementary Fig. 1 ). This indicates that the signal from the ligand-binding pocket is transferred through these helices and the conformations of the two pockets are strongly coupled. Our agonist-and antagonist-binding experiments indicate that this coupling also allows signal transfer in the reverse direction, from the G-protein-binding pocket to the ligandbinding pocket (Fig. 1) . CDR-H3 of Fab2838 locks the positions of helices III, VI and VII from the cytoplasmic side, leading to an inactive conformation of the extracellular ligand-binding pocket to which agonists cannot bind, probably because of the rearrangement of the E228   R102  III   IV   II   I   VIII  VII   VI  V   ICL3   ICL2   ICL1   ICL2   IV   II  ICL1   I  III   V   VI   VIII  VII   R131   E268   E247   R135   ICL3   ICL2   ICL1   VIII   VI   V   III   IV   VII   I  II   CDR-H3   E228   III   IV   II   I   VIII   VII   VI  V   ICL3   ICL2   ICL1   ICL2   IV   II ICL1   I  III   V   VI   VIII  VII   E247   R135   GαCT   ICL3   ICL2   ICL1   VIII   VI   V   III   IV   VII   I  II   VI  V   VII   VIII   I  II   III   E228   R102   ICL3   CDR-H3   ZM241385   VI   V   VII   ICL3   VIII   I  III   II 
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side chains at the bottom of the ligand-binding pocket including Trp 246 6.48 , which is the toggle switch for activation ( Supplementary Figs 1  and 11) . A similar conceptual model of b 2 AR activation has been reported 21 . In the case of b-adrenergic receptors, the conformations of the ligand-and G-protein-binding pockets are less strongly coupled, as demonstrated in the structures of b 1 AR-agonist complexes 22 and the b 2 AR/irreversible-agonist complex 23 . This may be because the A 2A AR and b 1 AR or b 2 AR agonists interact with different helices in the binding pockets (Supplementary Discussion).
Antibody fragments (and nanobodies) such as Nb80 and Fab2838, which recognize conformational epitopes of GPCRs, have great potential for GPCR studies in vitro and in vivo. Although antibodies recognizing the intracellular surface are not suitable for direct therapeutic use, the CDR structures should provide useful information for the design of peptides or small-molecule compounds against their clearly defined pockets to control the activation states of GPCRs. The antibody fragments will also be useful tools to study ligand-binding kinetics of GPCRs because they can separate ligand binding from equilibrium shifts between different activation states of the receptors. Our approach based on the conventional mouse hybridoma system allows us to raise antibodies against various receptors in three to four months using standard laboratory equipment.
METHODS SUMMARY
Expression and purification. A 2A AR N154Q (residues 1-316) was expressed in P. pastoris as described previously 24 and purified as described in Methods. Antibody generation. MRL/lpr mice were immunized with the purified A 2A AR with the antagonist ZM241385. Antibodies were raised to recognize conformational epitopes of A 2A AR using the conventional mouse hybridoma system 25 in combination with new screening methods as described in Methods. The Fab fragments were obtained by papain cleavage and purified by anion exchange column chromatography. Crystallographic data collection and structure determination. Purified A 2A AR was mixed with the Fab fragment and the A 2A AR-Fab complex was purified twice by gel filtration chromatography. Crystals were grown by vapour diffusion under the conditions described in Methods. Diffraction data were collected from a single cryo-cooled crystal on beamline I24 at the Diamond Light Source, UK. The structures were solved by molecular replacement using the receptor from the A 2A AR-T4L structure (PDB code, 3EML) and an antibody Fab fragment structure (PDB code, 1P7K) as search models. Data collection and refinement statistics are summarized in Supplementary Table 2 .
METHODS

Construction of A 2A AR expression vectors for Pichia pastoris.
The coding sequence of A 2A AR from residues 1 to 316 including the N-terminal a-factor, FLAG-tag sequence and C-terminal 103His-tag was synthesized by optimization of codon usage for P. pastoris (Takara Bio). In the construct, Asn 154 was also replaced by Gln to eliminate N-linked glycosylation. The DNA fragment was inserted into the multiple cloning site of the pPIC9K vector, and the linearized vector was transformed into the P. pastoris strain SMD1163 (Invitrogen) as described previously 24 . The transformed cells were stored as glycerol stocks at 280 uC. Expression and purification of A 2A AR. A 2A AR was expressed in P. pastoris as described previously 24 . Cells were suspended in buffer A (50 mM sodium phosphate, 100 mM NaCl, 5% glycerol, 2 mM EDTA, protease inhibitor cocktail (Roche); pH 7.4) and disrupted with glass beads (0.5 mm; Biospec) by vigorous agitation with a conventional orbital shaker at 350 r.p.m. for 2 h at 4 uC. Following removal of unbroken cells and cell debris at 10,000g, membranes were isolated by ultracentrifugation at 100,000g for 45 min. Membranes were resuspended in buffer B (20 mM HEPES, 500 mM NaCl, 30% glycerol, EDTA-free protease inhibitor cocktail (Roche); pH 7.0) and solubilized using 1% n-dodecyl b-D-maltoside (DDM; Anatrace) containing 0.2% cholesterol hemisuccinate (CHS; Sigma) in the presence of 4 mM theophylline (antagonist) for 1-2 h at 4 uC. After ultracentrifugation, the supernatant was supplemented with solid imidazole to a final concentration of 40 mM and incubated overnight with a TALON immobilized metal ion affinity chromatography resin (Clonetech) at 4 uC with gentle rotation (1 ml of TALON resin per 150 mg of total protein). The resin was washed with buffer C (20 mM HEPES, 250 mM NaCl, 10% glycerol, protease inhibitor cocktail, 0.05% DDM, 0.01% CHS; pH 7.0) containing 20 mM imidazole, and the bound A 2A AR was eluted with buffer C containing 300 mM imidazole. The purified sample was incubated overnight with ConA resin at 4 uC to remove contaminating glycosylated proteins and was collected in the flow-through fraction. The final purified sample was dialysed against buffer C and concentrated to approximately 20 mg ml 21 by ultrafiltration (ULTRA-4 100 K, Millipore). Construction, expression, and purification of A 2A AR-T4L. A 2A AR-T4L is a variant of A 2A AR in which the ICL3 region is replaced with a bacteriophage T4 lysozyme (T4L): Asn 2 to Tyr 161 of T4L were inserted between Leu 208 and Arg 222 within the ICL3 region, replacing residues Lys 209 to Ala 221. A 2A AR-T4L was expressed in P. pastoris and purified as described above. Antibody generation. All animal experiments described in this study conformed to the guidelines outlined in the Guide for the Care and Use of Laboratory Animals of Japan and were approved by the University of Tokyo Animal Care Committee (approval no. RAC07101).
To raise antibodies against conformational epitopes of A 2A AR, we modified existing protocols for immunization and screening of mouse monoclonal antibodies. A detailed description of these modified protocols will be published elsewhere. Briefly, MRL/lpr mice were immunized with 0.1 mg purified A 2A AR antagonist ZM241385 complex three times at two-week intervals. The immunized mice were killed and single-cell suspensions were prepared from their spleens. These cells were fused with NS-1 myeloma cells using polyethylene glycol (PEG) according to conventional methods 25 .
To screen antibodies that specifically recognize native receptors, we developed a novel ELISA method using proteoliposomes. For 'liposome-ELISA', we used purified A 2A AR reconstituted into liposomes containing biotinyl phosphatidylethanolamine (Avanti) to maintain the protein in its native conformation and effectively immobilize liposomes onto Streptavidin-coated plates (Nunc). To eliminate antibodies recognizing flexible loops, N (and C) termini or unstructured regions of A 2A AR, we performed ELISA using A 2A AR denatured with 1% sodium dodecyl sulphate. Denatured ELISA-negative cells were collected and evaluated using a BIAcore T100 (GE Healthcare) as described below. The selected cells were isolated by limiting dilution to establish monoclonal hybridoma cell lines producing antibodies against A 2A AR.
For large-scale antibody production, the monoclonal hybridoma cells were inoculated into BALB/c athymic nude mice. Immunoglobulin-G was collected from mouse ascites by precipitating twice with 50% ammonium sulphate and purified using Melon Gel (Thermo) according to the manufacturer's protocol. Fab fragments were obtained by proteolytic cleavage of immunoglobulin-G with papain (Worthington) and purified by anion exchange column chromatography (DEAE 5-PW, TOSOH). The sequences of Fab fragments were determined according to the standard 59-RACE method using total RNA isolated from hybridoma cells. Binding assay by surface plasmon resonance. The BIAcore T100 system and reagents, including sensor chips and amine coupling kit, were obtained from GE Healthcare. Monoclonal anti-mouse Fc antibody (200 mg ml 21 ; Millipore) was immobilized on a CM5 sensor chip using the amine coupling kit according to the manufacturer's instructions. Antibodies in hybridoma culture supernatants (50 ml) or purified monoclonal antibodies (50 mg ml 21 ) were tightly trapped by the Fc antibody fixed on the sensor chip. The antibodies bound tightly enough not to be released from the surface when it was washed with buffer D (20 mM HEPES, 100 mM NaCl, 0.05% DDM, 0.01% CHS; pH 7.0). Purified A 2A AR (or A 2A AR-T4L) was passed over the surface and the specific binding was monitored for 2 min at 20 uC. Subsequently, the sensor surface was washed with buffer D and the dissociation was monitored for 6 min at 20 uC. Association and dissociation rate constants (k on and k off ) were determined using a curve-fitting protocol as implemented in the BIAEVALUATION software (version 1.1, GE Healthcare) based on the Langmuir isotherm model assuming 1:1 binding stoichiometry. Ligand binding assays. Ligand binding assays were performed using radioligands of the antagonist [ 3 H]-ZM241385 and the agonist [ 3 H]-NECA (GE Healthcare). For single-point binding assays, 5 nM [ 3 H]-ZM241385 and 5 mM [ 3 H]-NECA were incubated in 50 ml of buffer D containing 5 or, respectively, 50 nM purified A 2A AR with or without 500 nM antibody for 1 h on ice. For saturation-binding assays, varying concentrations of [ 3 H]-ZM241385 and [ 3 H]-NECA were incubated in 50 ml of buffer D containing 5 or, respectively, 50 nM purified A 2A AR with or without 500 nM antibody (Fab2838) for 1 h on ice. Receptor-bound ligands were separated by gel filtration 26 and radioactivity was measured using a LS6500 scintillation counter (Beckman). Data were analysed by a nonlinear-regressionfitting program using the GraphPad PRISM software. Competition assays with antagonists (SCH442416, theophylline) and agonists (NECA, adenosine) were performed in the presence of 1.0 nM [ 3 H]-ZM241385 for A 2A AR or 1.5 nM [ 3 H]-ZM241385 for A 2A AR-Fab (corresponding to the respective K d values).
Purification and crystallization of the A 2A AR-Fab complex. Purified A 2A AR and the Fab fragments were mixed in a 1:1.2 molar ratio and were incubated on ice for 1 h. The mixture was loaded onto a Superdex 10/300 column (GE Healthcare) equilibrated with buffer C and eluted using the same buffer. The gel filtration step was repeated twice to ensure successful crystallization of the A 2A AR-Fab complex. Fractions containing the complex were concentrated to approximately 20 mg ml 21 by ultrafiltration (ULTRA-4 100 K, Millipore). Initial crystals were obtained using MemGold (Molecular Dimensions). After optimization, well-diffracting crystals were obtained in hanging drops by vapour diffusion at 20 uC with the protein solution containing 0.3-0.6% octylthioglucoside and the reservoir solution (1 ml) containing 30% PEG400, 0.1 M MES (pH 6.5) and 0.2 M MgCl 2 . Crystals appeared after one day and grew to maximum dimensions in one week before being flash-frozen and stored in liquid nitrogen. Data collection and structure determination. Diffraction data were collected from single cryo-cooled crystals (100 K) on beamline I24 at Diamond Light Source, UK, using a 10-mm focused beam (wavelength, 0.9795 Å ) and a PILATUS 6M detector (Dectris). Data were processed using MOSFLM and SCALA from the CCP4 program suite 27 . The structure was initially solved using the data at 2.7 Å . Molecular replacement was carried out with PHASER 28 using the receptor from the A 2A AR-T4L fusion structure (PDB code, 3EML) and an antibody fragment (PDB code, 1P7K) as search models. Iterative cycles of model building and structure refinement were performed using COOT 29 , REFMAC5 30 and phenix.refine in the PHENIX program package 31 . The final model from this refinement was used as the initial model for refinement against the data at 3.1 Å . The refinement was carried out as above. Model validation was performed using PROCHECK 32 and MOLPROBITY 33 . The resulting crystallographic and refinement statistics are summarized in Supplementary Table 2 . Disordered region of A 2A AR was predicted by the RONN program 34 . Figures were prepared using PYMOL 35 .
